| Some keys to the literature | p. xiii |
| Contributing authors | p. xxiii |
| Preface, first edition | p. xxix |
| Preface, second edition | p. xxxi |
| Preface, third edition | p. xxxiii |
| Preface, fourth edition | p. xxxv |
| Preface, fifth edition | p. xxvii |
| Pressure induced and metabolic alterations in the glomerulus: Role in cytokine activity and progressive sclerosis | p. 1 |
| Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests | p. 13 |
| Retinopathy in relation to albuminuria and blood pressure in IDDM | p. 29 |
| Microalbuminuria and cardiovascular disease | p. 39 |
| The heart in diabetes: results of trials | p. 55 |
| Albuminuria in non-insulin-dependent diabetes - renal or "extra" renal disease? | p. 67 |
| The clinical course of renal disease in Caucasian NIDDM-patients | p. 81 |
| Serum creatinine and other measures of GFR in diabetes | p. 95 |
| Familial factors in diabetic nephropathy | p. 103 |
| Genetics and diabetic nephropathy | p. 115 |
| Birth, Barker and Brenner: The concept of low birth weight and renal disease | p. 129 |
| Effect of insulin on the kidney and the cardiovascular system | p. 141 |
| Value of screening for microalbuminuria in people with diabetes as well as in the general population | p. 155 |
| Incidence of nephropathy in IDDM as related to mortality. Cost and benefits of early intervention | p. 169 |
| Dysfunction of the vascular endothelium and the development of renal and vascular complications in diabetes | p. 179 |
| Urinary tract infections in patients with diabetes mellitus | p. 193 |
| Light microscopy of diabetic glomerulopathy: the classic lesions | p. 201 |
| Renal structural changes in patients with type 1 diabetes and microalbuminuria | p. 211 |
| Renal structure in type 2 diabetic patients with microalbuminuria | p. 225 |
| Nephropathy in NIDDM patients, predictors of outcome | p. 237 |
| Advanced glycation end-products and diabetic renal disease | p. 247 |
| Protein kinase C in diabetic renal involvement, the perspective of inhibition | p. 255 |
| Biochemical aspects of diabetic nephropathy | p. 263 |
| Pathogenesis of diabetic glomerulopathy: the role of glomerular hemodynamic factors | p. 281 |
| An update on the role of growth factors in the development of diabetic kidney disease | p. 295 |
| Transforming growth factor-[beta] and other cytokines in experimental and human diabetic nephropathy | p. 313 |
| Blood pressure elevation in diabetes: the results from 24-h ambulatory blood pressure recordings | p. 339 |
| Microalbuminuria in young patients with type 1 diabetes | p. 363 |
| Early renal hyperfunction and hypertrophy in IDDM patients including comments on early intervention | p. 381 |
| Diabetes, hypertension, and kidney disease in the Pima Indians | p. 395 |
| Autoregulation of glomerular filtration rate in patients with diabetes | p. 407 |
| ACE-inhibition, angiotensin II receptor blockade, and diabetic nephropathy | p. 417 |
| The concept of incipient diabetic nephropathy and effect of early antihypertensive intervention | p. 423 |
| Reversibility of diabetic nephropathy lesions: A new concept | p. 435 |
| Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria | p. 441 |
| Addendum regarding renovascular hypertension and renal artery stenosis (especially NIDDM) | |
| The course of incipient and overt diabetic nephropathy: the perspective of more optimal treatment, including UKPDS-perspective | p. 461 |
| Non-glycaemic intervention in diabetic nephropathy: the role of dietary protein intake | p. 473 |
| Diabetic nephropathy and pregnancy | p. 487 |
| Evolution worldwide of renal replacement therapy in diabetes | p. 501 |
| Haemodialysis and CAPD in type 1 and type 2 diabetic patients with endstage renal failure | p. 513 |
| Renal transplantation for diabetic nephropathy | p. 527 |
| Combination therapy for hypertension and renal disease in diabetes | p. 559 |
| Microalbuminuria in essential hypertension. Significance for the cardiovascular and renal systems | p. 575 |
| A comparison of progression in diabetic and non-diabetic renal disease: similarity of progression promoters | p. 587 |
| Update of the latest intervention trials in hypertension and type 2 diabetes | p. 601 |
| Scientific basis for the new guidelines for the treatment of hypertension in type 2 diabetes | p. 611 |
| Regulatory considerations in the development of therapies for diabetic nephropathy and related conditions | p. 623 |
| The renin angiotensin system in the pathogenesis of diabetic complications | p. 645 |
| Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas | p. 655 |
| Table of Contents provided by Syndetics. All Rights Reserved. |